Table 1.
Baseline Demographics and Characteristics
| Denosumab (n = 321) | Zoledronic Acid (n = 322) | |
|---|---|---|
| Age, y, mean (SD) | 68.5 (7.1) | 69.5 (7.7) |
| Race/ethnic group, n, % | ||
| White or Caucasian | 309 (96.3) | 314 (97.5) |
| Asian | 5 (1.6) | 4 (1.2) |
| Black or African American | 1 (0.3) | 0 |
| Othera | 6 (1.8) | 4 (1.2) |
| BMI, kg/m2, mean (SD) | 24.3 (4.0) | 24.3 (4.2) |
| Years since menopause, mean (SD) | 19.9 (8.2) | 20.8 (8.9) |
| History of fracture, n, % | ||
| Any | 169 (52.6) | 159 (49.4) |
| Osteoporotic | 120 (37.4) | 121 (37.6) |
| Nonvertebral | 109 (34.0) | 106 (32.9) |
| Vertebral | 24 (7.5) | 28 (8.7) |
| Lumbar spine BMD T-score | ||
| Mean (SD) | −2.74 (0.83) | −2.64 (0.86) |
| ≤−2.5, n, % | 230 (71.7) | 229 (71.1) |
| >−2.5, n, % | 91 (28.3) | 91 (28.3) |
| Total hip BMD T-score | ||
| Mean (SD) | −1.93 (0.74) | −1.93 (0.80) |
| ≤−2.5, n, % | 74 (23.1) | 75 (23.3) |
| >−2.5, n, % | 246 (76.6) | 243 (75.5) |
| Prior oral bisphosphonate treatment duration, y, mean (SD) | 6.2 (3.8) | 6.4 (3.7) |
| Serum CTX, pg/mL, median (Q1, Q3) | 209 (146, 303) | 212 (151, 297) |
| Serum CTX,b pg/mL, median (Q1, Q3) | 211 (134, 303) | 194 (133, 292) |
| Serum P1NP,b ng/mL, median (Q1, Q3) | 26 (16, 34) | 23 (19, 32) |
| Serum iPTH,b ng/mL, median (Q1, Q3) | 39 (29, 49) | 36 (29, 51) |
Abbreviations: Q1, quartile 1; Q3, quartile 3.
a
Includes subjects who self-identified as Native, Native Hawaiian, or other Pacific Islander, multiple, or other.
b
Data represent subjects enrolled in the bone turnover marker substudy.